Cassandra Fleming

Dr. Cassandra Fleming


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2018 in Journal of the American Chemical Society
Verified
Journal Article
Open access
CFCassandra Fleming
Cassandra Fleming
SLShiming Li
Shiming Li
MGMorten Grøtli
Morten Grøtli
JAJoakim Andréasson
Joakim Andréasson
Photochromic molecules from the spiropyran family are known to undergo light-induced interconversion between the colorless spiro- and the colored merocyanine forms. Here, we show for the first time that small structural modifications open up for an additional photoisomerization mode: reversible cis–trans isomerization of the merocyanine. Moreover, the introduction of a photocage allows for light-activated switching between the two modes.

1 September 2016 in Cell Reports
Verified
Journal Article
Open access
VGVidhi Gaur
Vidhi Gaur
TCTimothy Connor
Timothy Connor
ASAndrew Sanigorski
Andrew Sanigorski
SMSheree D. Martin
Sheree D. Martin
CBClinton Bruce
Clinton Bruce
SMSean L. McGee
Sean L. McGee
Drugs that recapitulate aspects of the exercise adaptive response have the potential to provide better treatment for diseases associated with physical inactivity. We previously observed reduced skeletal muscle class IIa HDAC (histone deacetylase) transcriptional repressive activity during exercise. Here, we find that exercise-like adaptations are induced by skeletal muscle expression of class IIa HDAC mutants that cannot form a corepressor complex. Adaptations include increased metabolic gene expression, mitochondrial capacity, and lipid oxidation. An existing HDAC inhibitor, Scriptaid, had similar phenotypic effects through disruption of the class IIa HDAC corepressor complex. Acute Scriptaid administration to mice increased the expression of metabolic genes, which required an intact class IIa HDAC corepressor complex. Chronic Scriptaid administration increased exercise capacity, whole-body energy expenditure and lipid oxidation, and reduced fasting blood lipids and glucose. Therefore, compounds that disrupt class IIa HDAC function could be used to enhance metabolic health in chronic diseases driven by physical inactivity.

30 January 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
CFCassandra Fleming
Cassandra Fleming
TATrent Ashton
Trent Ashton
VGVidhi Gaur
Vidhi Gaur
SMSean L. McGee
Sean L. McGee
FPFrederick M. Pfeffer
Frederick M. Pfeffer

2 April 2015 in Chemical Communications
Verified
Journal Article
Open access
PDF file
CFCassandra Fleming
Cassandra Fleming
TATrent Ashton
Trent Ashton
CNCameron Nowell
Cameron Nowell
MDMark Devlin
Mark Devlin
ANAnthony Natoli
Anthony Natoli
FPFrederick M. Pfeffer
Frederick M. Pfeffer
Fluorescence microscopy studies using 4-morpholinoscriptaid (4MS) demonstrated rapid cellular uptake of this scriptaid analogue into the cytoplasm but no nuclear penetration. As 4MS and scriptaid have the same in vitro activity against HDACs and KASUMI-1 cells; 4MS exemplifies a rational approach to subtly modify ‘profluorogenic’ substrates for intracellular studies.

21 August 2024 in Chempluschem
Verified
Journal Article
Open access
MCMegan R. Clotworthy
Megan R. Clotworthy
JDJoseph J. M. Dawson
Joseph J. M. Dawson
MJMark D. Johnstone
Mark D. Johnstone
CFCassandra Fleming
Cassandra Fleming
The development of light‐responsive molecular tools enables spatiotemporal control of biochemical processes with superior precision. Amongst these molecular tools, photolabile caging groups are employed to prevent critical binding interactions between a bioactive molecule and its corresponding target. Only upon irradiation with light, the bioactive is released in its ‘active’ form and is now readily available to bind to its target. Coumarin‐derived caging groups constitute one of the most popular classes of photolabile protecting groups, due to their facile synthetic accessibility, ease of tuning photophysical properties via structural modification and rapid photolysis reactions. Herein, we highlight the recent progress made on the development of coumarin‐derived caging groups, in which the red‐shifting of absorption spectra, improving aqueous solubility and tailoring sub‐cellular localisation has been of particular interest.

21 April 2022 in Chemistry – An Asian Journal
Verified
Journal Article
Open access
DLDóra Laczi
Dóra Laczi
MJMark D. Johnstone
Mark D. Johnstone
CFCassandra Fleming
Cassandra Fleming
The development of new and effective therapeutics is reliant on the ability to study the underlying mechanisms of potential drug targets in live cells and multicellular systems. A persistent challenge in many drug development programmes is poor selectivity, which can obscure the mechanisms involved and lead to poorly understood modes of action. In efforts to improve our understanding of these complex processes, small molecule inhibitors have been developed in which their OFF/ON therapeutic activity can be toggled using light. Photopharmacology is devoted to using light to modulate drugs. Herein, we highlight the recent progress made towards the development of light‐responsive small molecule inhibitors of selected enzymatic targets. Given the size of this field, literature from 2015 onwards has been reviewed.